Compare Stocks: LIAN, PLRZ, BGM, and TXMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$0.25 -1.1%	$0.28	$0.23 ▼ $10.68	$23.92M	1.8	279,287 shs	180,205 shs
LIAN LianBio	$0.06	$0.05	$0.27 ▼ $4.99	$6.43M	0.23	1.04 million shs	166 shs
PLRZ Polyrizon	$10.78 +2.5%	$11.67	$2.88 ▼ $18.20	$25.86M	-1.39	64,709 shs	711 shs
TXMD TherapeuticsMD	$2.04 -4.2%	$2.11	$0.99 ▼ $2.95	$23.60M	0.65	46,636 shs	9,160 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-2.47%	-3.98%	-6.15%	-23.03%	-97.70%
LIAN LianBio	0.00%	0.00%	+87.70%	-62.79%	-0.34%
PLRZ Polyrizon	-5.82%	-4.71%	-3.58%	-8.45%	+63.71%
TXMD TherapeuticsMD	-1.84%	-2.29%	-6.58%	+0.95%	+97.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$0.25 -1.1%	$0.28	$0.23 ▼ $10.68	$23.92M	1.8	279,287 shs	180,205 shs
LIAN LianBio	$0.06	$0.05	$0.27 ▼ $4.99	$6.43M	0.23	1.04 million shs	166 shs
PLRZ Polyrizon	$10.78 +2.5%	$11.67	$2.88 ▼ $18.20	$25.86M	-1.39	64,709 shs	711 shs
TXMD TherapeuticsMD	$2.04 -4.2%	$2.11	$0.99 ▼ $2.95	$23.60M	0.65	46,636 shs	9,160 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-2.47%	-3.98%	-6.15%	-23.03%	-97.70%
LIAN LianBio	0.00%	0.00%	+87.70%	-62.79%	-0.34%
PLRZ Polyrizon	-5.82%	-4.71%	-3.58%	-8.45%	+63.71%
TXMD TherapeuticsMD	-1.84%	-2.29%	-6.58%	+0.95%	+97.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	1.00	Sell	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A
PLRZ Polyrizon	1.00	Sell	N/A	N/A
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIAN, PLRZ, BGM, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/18/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/14/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/6/2026	BGM BGM Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$37.92M	0.63	N/A	N/A	$4.03 per share	0.06
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A
TXMD TherapeuticsMD	$3.02M	7.82	$0.04 per share	46.30	$2.32 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	-$570K	$0.02	102.00	N/A	N/A	-6.64%	-1.09%	-0.78%	11/17/2026 (Estimated)

Latest LIAN, PLRZ, BGM, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q2 2026	BGM BGM Group	N/A	-$0.01	N/A	-$0.0050	N/A	$12.15 million
8/11/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.87 million
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$2.69	N/A	-$2.6850	N/A	$11.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.25	0.73
LIAN LianBio	N/A	10.06	10.06
PLRZ Polyrizon	N/A	29.03	29.03
TXMD TherapeuticsMD	N/A	3.22	3.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
LIAN LianBio	74.85%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
LIAN LianBio	7.59%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	471	97.22 million	40.19 million	N/A
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PLRZ Polyrizon	1	2.40 million	N/A	N/A
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

LIAN, PLRZ, BGM, and TXMD Headlines

Recent News About These Companies

Critical Contrast: Nutriband (NASDAQ:NTRB) versus TherapeuticsMD (NASDAQ:TXMD)

September 16, 2026 | americanbankingnews.com

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LIAN, PLRZ, BGM, and TXMD Company Descriptions

BGM Group NASDAQ:BGM

$0.25 0.00 (-1.09%)

As of 03:36 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

LianBio NASDAQ:LIAN

$0.06 0.00 (0.00%)

As of 09/24/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Polyrizon NASDAQ:PLRZ

$10.78 +0.27 (+2.52%)

As of 03:27 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

TherapeuticsMD NASDAQ:TXMD

$2.04 -0.09 (-4.23%)

As of 03:04 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIAN, PLRZ, BGM, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIAN, PLRZ, BGM, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIAN, PLRZ, BGM, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIAN, PLRZ, BGM, and TXMD Company Descriptions

BGM Group NASDAQ:BGM

LianBio NASDAQ:LIAN

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIAN, PLRZ, BGM, and TXMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIAN, PLRZ, BGM, and TXMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIAN, PLRZ, BGM, and TXMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIAN, PLRZ, BGM, and TXMD Company Descriptions

BGM Group NASDAQ:BGM

LianBio NASDAQ:LIAN

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools